Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Title:
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Author:
Hoppe, Jordana E Kasi, Ajay S Pittman, Jessica E Jensen, Renee Thia, Lena P Robinson, Philip Tirakitsoontorn, Pornchai Ramsey, Bonnie Mall, Marcus A Taylor-Cousar, Jennifer L McKone, Edward F Tullis, Elizabeth Salinas, Danieli B Zhu, Jiaqiang Chen, Yih-Chieh Rodriguez-Romero, Violeta Sosnay, Patrick R Davies, Gwyneth
Appeared in:
Lancet respiratory medicine
Paging:
Volume 13 () nr. 3 pages 244-255
Year:
2025
Contents:
Publisher:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license